289 related articles for article (PubMed ID: 17419949)
1. PDGF receptors as targets in tumor treatment.
Ostman A; Heldin CH
Adv Cancer Res; 2007; 97():247-74. PubMed ID: 17419949
[TBL] [Abstract][Full Text] [Related]
2. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting.
Pietras K; Pahler J; Bergers G; Hanahan D
PLoS Med; 2008 Jan; 5(1):e19. PubMed ID: 18232728
[TBL] [Abstract][Full Text] [Related]
3. Targeting PDGF signaling in carcinoma-associated fibroblasts controls cervical cancer in mouse model.
Jain RK; Lahdenranta J; Fukumura D
PLoS Med; 2008 Jan; 5(1):e24. PubMed ID: 18232729
[TBL] [Abstract][Full Text] [Related]
4. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
Servidei T; Riccardi A; Sanguinetti M; Dominici C; Riccardi R
J Cell Physiol; 2006 Jul; 208(1):220-8. PubMed ID: 16575905
[TBL] [Abstract][Full Text] [Related]
5. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma.
Ostman A
Cytokine Growth Factor Rev; 2004 Aug; 15(4):275-86. PubMed ID: 15207817
[TBL] [Abstract][Full Text] [Related]
6. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB.
Shimizu A; O'Brien KP; Sjöblom T; Pietras K; Buchdunger E; Collins VP; Heldin CH; Dumanski JP; Ostman A
Cancer Res; 1999 Aug; 59(15):3719-23. PubMed ID: 10446987
[TBL] [Abstract][Full Text] [Related]
7. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
Potapova O; Laird AD; Nannini MA; Barone A; Li G; Moss KG; Cherrington JM; Mendel DB
Mol Cancer Ther; 2006 May; 5(5):1280-9. PubMed ID: 16731761
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells.
Kinoshita K; Nakagawa K; Hamada J; Hida Y; Tada M; Kondo S; Moriuchi T
Int J Oncol; 2010 Oct; 37(4):869-77. PubMed ID: 20811709
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content.
McCarty MF; Somcio RJ; Stoeltzing O; Wey J; Fan F; Liu W; Bucana C; Ellis LM
J Clin Invest; 2007 Aug; 117(8):2114-22. PubMed ID: 17641778
[TBL] [Abstract][Full Text] [Related]
10. Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor.
Rosenberg A; Mathew P
Expert Opin Investig Drugs; 2013 Jun; 22(6):787-94. PubMed ID: 23540855
[TBL] [Abstract][Full Text] [Related]
11. Increasing tumor uptake of anticancer drugs with imatinib.
Pietras K
Semin Oncol; 2004 Apr; 31(2 Suppl 6):18-23. PubMed ID: 15176000
[TBL] [Abstract][Full Text] [Related]
12. Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model.
Sumida T; Kitadai Y; Shinagawa K; Tanaka M; Kodama M; Ohnishi M; Ohara E; Tanaka S; Yasui W; Chayama K
Int J Cancer; 2011 May; 128(9):2050-62. PubMed ID: 21387285
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.
Lev DC; Kim SJ; Onn A; Stone V; Nam DH; Yazici S; Fidler IJ; Price JE
Clin Cancer Res; 2005 Jan; 11(1):306-14. PubMed ID: 15671560
[TBL] [Abstract][Full Text] [Related]
14. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
Pietras K; Hanahan D
J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
[TBL] [Abstract][Full Text] [Related]
15. Current management of GIST.
Blanke C
Clin Adv Hematol Oncol; 2004 May; 2(5):280, 283. PubMed ID: 17682286
[No Abstract] [Full Text] [Related]
16. Platelet-derived growth factor receptors: a therapeutic target in solid tumors.
George D
Semin Oncol; 2001 Oct; 28(5 Suppl 17):27-33. PubMed ID: 11740804
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors.
Pietras K; Ostman A; Sjöquist M; Buchdunger E; Reed RK; Heldin CH; Rubin K
Cancer Res; 2001 Apr; 61(7):2929-34. PubMed ID: 11306470
[TBL] [Abstract][Full Text] [Related]
18. PDGF BB induces VEGF secretion in ovarian cancer.
Matei D; Kelich S; Cao L; Menning N; Emerson RE; Rao J; Jeng MH; Sledge GW
Cancer Biol Ther; 2007 Dec; 6(12):1951-9. PubMed ID: 18075302
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib for imatinib-resistant GIST.
Joensuu H
Lancet; 2006 Oct; 368(9544):1303-4. PubMed ID: 17046443
[No Abstract] [Full Text] [Related]
20. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.
Pietras K; Rubin K; Sjöblom T; Buchdunger E; Sjöquist M; Heldin CH; Ostman A
Cancer Res; 2002 Oct; 62(19):5476-84. PubMed ID: 12359756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]